In 1984, Srivastava and Das et al. found that the subcutaneous injection of 90 to 100 kDa proteins derived from autologous tumor cells activated humoral immune responses in a liver cancer mouse model, which initiated the use of gp96 in immunotherapy methods [24]. This evidence concerns the gene HSP90B1 and neoplasm.